What did @mj.gandon actually say?
The creator's core argument is that some peptides require cycling while others are safe for continuous use. They name "pteromornin" and "tussomorlornin" (almost certainly tesamorelin and sermorelin) as peptides that cause water retention if used continuously, and they hold up NAD as a longevity peptide you can stay on indefinitely. The video ends with a call to DM their clinic for protocol advice.
To be fair, the creator is touching on a real clinical conversation. Growth hormone secretagogues do carry considerations around continuous use. But the way these claims are delivered, confidently and without nuance, on a 35K-view TikTok, deserves a closer look.
Does the science back this up?
Partially, yes. The water retention concern with growth hormone-stimulating peptides is real and documented. But the framing oversimplifies a complicated picture.
Tesamorelin, the only FDA-approved growth hormone-releasing hormone (GHRH) analog, has Phase III trial data (Falutz et al., 2010, New England Journal of Medicine) showing it can cause fluid retention as a side effect, particularly at higher exposures. Sermorelin, an older GHRH analog, has similar pharmacodynamic effects and similar risk profiles for edema at supraphysiological GH stimulation levels.
However, saying these peptides "might cause a lot of water retention" if you stay on them conflates a dose-dependent side effect with an argument for cycling as the fix. Cycling is one mitigation strategy. Dose reduction is another. The evidence base for cycling protocols specifically is largely anecdotal and not drawn from randomized controlled trial data.
As for NAD being safe for continuous use: NAD precursors like NMN and NR have emerging but limited long-term human safety data (Yoshino et al., 2021, Science). Calling it firmly safe for indefinite use is ahead of the evidence.
What did they get wrong (or right)?
They got the general direction right: growth hormone secretagogues do warrant more careful protocol management than something like a B-vitamin. Credit where it's due.
But there are real problems here.
- The creator mispronounces both peptide names badly enough that a viewer might not know what peptides are actually being discussed. That's not just a cosmetic issue. People make purchasing and dosing decisions based on this content.
- The claim that water retention is the primary reason to cycle tesamorelin or sermorelin skips over more significant concerns: receptor desensitization, suppression of endogenous GH pulsatility, and IGF-1 elevation with prolonged use. Water retention is the least of it.
- Calling NAD a "longevity peptide" is inaccurate by definition. NAD (nicotinamide adenine dinucleotide) is a coenzyme, not a peptide. This is a basic category error that a clinic-affiliated account probably should not be making.
- The call to DM for protocol advice is a compliance concern. Recommending peptide cycling protocols via social media DMs is not the same as a supervised clinical intake.
What should you actually know?
If you're using or considering growth hormone secretagogues, here's what the actual evidence suggests.
Tesamorelin has the strongest clinical evidence of any GHRH analog because it went through the full FDA approval process for HIV-associated lipodystrophy. That approval was for a specific population, at a specific dose, for a specific duration. Off-label use in healthy adults for body composition or longevity is not supported by the same evidence base.
Sermorelin has older clinical data and a shorter half-life than tesamorelin, which some clinicians argue makes it less likely to cause tachyphylaxis. But again, the cycling protocols circulating in wellness spaces are not backed by published trials.
NAD precursor supplementation (typically NMN or NR, not injectable NAD itself) has shown some promise in early human trials for metabolic and cellular health markers (Mills et al., 2016, Cell Metabolism). But long-term safety data in humans is still accumulating. Saying you "prefer for you to stay on this peptide" indefinitely is a stronger claim than the current evidence supports, and again, it's not a peptide.
Anyone using these compounds should be doing so under direct clinical supervision with baseline labs, periodic IGF-1 monitoring, and a protocol that accounts for their individual health status.